QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 hc-wainwright--co-reiterates-buy-on-genmab-maintains-50-price-target

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Genmab (NASDAQ:GMAB) with a Buy and maintains $50 price target.

 reported-sunday-genmabs-rinatabart-sesutecan-shows-anti-tumor-activity-in-heavily-pretreated-ovarian-and-endometrial-cancer-patients-in-phase-12-trial

Treatment with rinatabart sesutecan (Rina-S) showed encouraging response rate in heavily pretreated patients with ovarian can...

 hc-wainwright--co-reiterates-buy-on-genmab-maintains-50-price-target

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Genmab (NASDAQ:GMAB) with a Buy and maintains $50 price target.

 morgan-stanley-maintains-equal-weight-on-genmab-maintains-31-price-target

Morgan Stanley analyst Vikram Purohit maintains Genmab (NASDAQ:GMAB) with a Equal-Weight and maintains $31 price target.

 expert-ratings-for-genmab
Expert Ratings For Genmab
09/09/2024 14:00:57

 truist-securities-maintains-buy-on-genmab-lowers-price-target-to-50

Truist Securities analyst Asthika Goonewardene maintains Genmab (NASDAQ:GMAB) with a Buy and lowers the price target from $5...

 morgan-stanley-reinstates-equal-weight-on-genmab-announces-31-price-target

Morgan Stanley analyst Vikram Purohit reinstates Genmab (NASDAQ:GMAB) with a Equal-Weight and announces $31 price target.

 hc-wainwright--co-reiterates-buy-on-genmab-maintains-50-price-target

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Genmab (NASDAQ:GMAB) with a Buy and maintains $50 price target.

 hc-wainwright--co-reiterates-buy-on-genmab-maintains-50-price-target

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Genmab (NASDAQ:GMAB) with a Buy and maintains $50 price target.

 jp-morgan-downgrades-genmab-to-neutral

JP Morgan analyst James Gordon downgrades Genmab (NASDAQ:GMAB) from Overweight to Neutral.

Core News & Articles

TEPKINLY is the first and only subcutaneous bispecific antibody approved as a monotherapy in the European Union to treat both r...

 hc-wainwright--co-reiterates-buy-on-genmab-maintains-50-price-target

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Genmab (NASDAQ:GMAB) with a Buy and maintains $50 price target.

 genmab-updates-fy24-revenue-guidance-from-dkk-187b--205b-to-dkk-205b--217b-reflecting-continued-strong-growth-of-darzalex-and-kesimpta-net-sales

Genmab updates its 2024 financial guidanceIncrease in revenue driven by higher royalties and reimbursement revenueIncrease in o...

 hc-wainwright--co-reiterates-buy-on-genmab-maintains-50-price-target

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Genmab (NASDAQ:GMAB) with a Buy and maintains $50 price target.

 biontechs-q2-loss-widens-amid-low-demand-for-its-pfizer-partnered-covid-19-vaccine-increases-rd-spending-on-new-cancer-products

BioNTech posted a significant Q2 2024 loss of 807.8 million euros. Sales dropped to 128.7 million euros as the demand for COVID...

Core News & Articles

 Genmab A/S (NASDAQ: GMAB) announced today that it will assume sole responsibility for the continued development and potential ...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION